pharmaceuticals Article Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci 1, 1, 2 3 3 Eric Mühlberg y, Florian Umstätter y, Cornelius Domhan , Tobias Hertlein , Knut Ohlsen , Andreas Krause 1, Christian Kleist 1, Barbro Beijer 1, Stefan Zimmermann 4, Uwe Haberkorn 1,5, Walter Mier 1 and Philipp Uhl 1,* 1 Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany;
[email protected] (E.M.);
[email protected] (F.U.);
[email protected] (A.K.);
[email protected] (C.K.);
[email protected] (B.B.);
[email protected] (U.H.);
[email protected] (W.M.) 2 Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany;
[email protected] 3 Institute for Molecular Infection Biology, University of Würzburg, Josef-Schneider-Straße 2/D15, 97080 Würzburg, Germany;
[email protected] (T.H.);
[email protected] (K.O.) 4 Department of Medical Microbiology and Hygiene, Heidelberg University Hospital, Im Neuenheimer Feld 324, 69120 Heidelberg Germany;
[email protected] 5 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 260, 69120 Heidelberg, Germany * Correspondence:
[email protected]; Tel.: +49-6221-56-7726 These authors contributed equally. y Received: 23 April 2020; Accepted: 27 May 2020; Published: 29 May 2020 Abstract: Multidrug-resistant bacteria represent one of the most important health care problems worldwide. While there are numerous drugs available for standard therapy, there are only a few compounds capable of serving as a last resort for severe infections.